Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer
MSK and Resolution Bioscience (a part of Agilent) investigate clinical utility of the Resolution ctDx Lung in large prospective cohort
Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to discuss the Resolution ctDx Lung, a laboratory-developed test (LDT) developed by Resolution Bioscience. Read more